Background
Patients and methods
Characteristic | |
---|---|
Median age at Re-RT (years) | 53.5 |
Range: age at Re-RT (years) | 21.8 – 81.1 |
< 50 years at Re-RT | 26/64 (40.6%) |
≥ 50 years at Re-RT | 38/64 (59.4%) |
Male | 34/64 (53.1%) |
Female | 30/64 (46.9%) |
WHO IV | 53/64 (82.8%) |
WHO III | 11/64 (17.2%) |
Karnofsky performance score < 70 | 13/64 (20.3%) |
Karnofsky performance score ≥ 70 | 51/64 (79.7%) |
Median time (RT to Re-RT) (months) | 13.4 |
Range: time (RT to Re-RT) (months) | 2.7 – 202.6 |
Time from RT to Re-RT ≤ 12 months | 21/64 (32.8%) |
Time from RT to Re-RT > 12 months | 43/64 (67.2%) |
Concurrent chemotherapy | 36/64 (56.3%) |
Carboplatin/etoposide | 24/64 (37.5%) |
Temozolomide | 12/64 (18.8%) |
Complete resection before Re-RT | 8/64 (12.5%) |
Incomplete/no resection before Re-RT | 56/64 (87.5%) |
First-line treatment
Second-line treatment
Characteristic | OS-6 (%) | mOS (months) | p= |
---|---|---|---|
< 50 years at Re-RT | 73 ± 9 | 9.4 ± 1.4 | 0.015 |
≥ 50 years at Re-RT | 50 ± 8 | 5.8 ± 1.4 | |
Male | 60 ± 9 | 7.7 ± 0.8 | 0.669 |
Female | 59 ± 9 | 7.7 ± 1.7 | |
WHO IV | 55 ± 7 | 7.4 ± 1.4 | 0.009 |
WHO III | 82 ± 12 | 11.2 ± 10.5 | |
Karnofsky performance score < 70 | 34 ± 14 | 5.0 ± 1.0 | 0.002 |
Karnofsky performance score ≥ 70 | 66 ± 7 | 8.1 ± 0.8 | |
Time from RT to Re-RT ≤ 12 months | 52 ± 11 | 6.9 ± 2.5 | 0.140 |
Time from RT to Re-RT > 12 months | 63 ± 8 | 8.1 ± 1.1 | |
No concurrent chemotherapy1 | 52 ± 10 | 6.6 ± 2.9 | 0.001 (3 vs 2) |
Carboplatin/etoposide2 | 54 ± 10 | 6.7 ± 1.3 | 0.006 (3 vs 1) |
Temozolomide3 | 92 ± 8 | 27.0 ± 17.6 | 0.455 (2 vs 1) |
Complete resection before Re-RT | 100 | 17.5 ± 3.4 | 0.034 |
Incomplete/no resection before Re-RT | 55 ± 7 | 7.4 ± 1.3 |
Histology at primary diagnosis
Histology at reirradiation
Statistics
Univariate analyses
Multivariate analysis
Prognostic score for survival after reirradiation
Results
Outcome
Prognostic factors for OS in univariate analysis
Categorical variables, Kaplan Meier method, log rank test
Continous variables, Cox proportional hazards regression analysis
Prognostic factors for overall survival in multivariate (cox proportional hazards regression) analysis
Reassessment of the prognostic score for overall survival after reirradiation of relapsed gliomas
Toxicity
All patients (n = 64) | PTV ≤ 110 ml (n = 32) | PTV > 110 ml (n = 32) | |
---|---|---|---|
Headache (≤ II° CTC) | 7/64 (10.9%) | 2/32 (6.3%) | 5/32 (15.6%) |
Nausea/vomiting (≤ II° CTC) | 4/64 (6.3%) | 3/32 (9.3%) | 1/32 (3.1%) |
Seizures (≤ II° CTC) | 5/64 (7.8%) | 2/32 (6.2%) | 3/32 (9.3%) |
Skin reaction (≤ II° CTC) | 7/64 (10.9%) | 3/32 (9.3%) | 4/32 (12.5%) |
Mucosa reaction (≤ II° CTC) | 2/64 (3.1%) | 1/32 (3.1%) | 1/32 (3.1%) |
Ear toxicity (≤ II° CTC) | 0/64 (0%) | 0/64 (0%) | 0/64 (0%) |
Infections (≤ II° CTC) | 3/64 (4.6%) | 1/32 (3.1%) | 2/32 (6.3%) |